MetLife Investment Management’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $365K | Buy |
138,264
+74,106
| +116% | +$196K | ﹤0.01% | 1836 |
|
|
2025
Q1 | $193K | Sell |
64,158
-25,235
| -28% | -$76K | ﹤0.01% | 2222 |
|
|
2024
Q4 | $229K | Buy |
89,393
+27,028
| +43% | +$69.2K | ﹤0.01% | 2238 |
|
|
2024
Q3 | $232K | Sell |
62,365
-19,928
| -24% | -$74.1K | ﹤0.01% | 2211 |
|
|
2024
Q2 | $520K | Buy |
82,293
+13,446
| +20% | +$85K | ﹤0.01% | 1701 |
|
|
2024
Q1 | $370K | Sell |
68,847
-1,977
| -3% | -$10.6K | ﹤0.01% | 1835 |
|
|
2023
Q4 | $356K | Buy |
70,824
+12,345
| +21% | +$62K | ﹤0.01% | 1893 |
|
|
2023
Q3 | $98.8K | Hold |
58,479
| – | – | ﹤0.01% | 2580 |
|
|
2023
Q2 | $163K | Buy |
58,479
+41,583
| +246% | +$116K | ﹤0.01% | 2398 |
|
|
2023
Q1 | $30.8K | Sell |
16,896
-27,163
| -62% | -$49.4K | ﹤0.01% | 2757 |
|
|
2022
Q4 | $223K | Hold |
44,059
| – | – | ﹤0.01% | 2187 |
|
|
2022
Q3 | $219K | Buy |
44,059
+18,454
| +72% | +$91.7K | ﹤0.01% | 2243 |
|
|
2022
Q2 | $95.3K | Sell |
25,605
-7,653
| -23% | -$28.5K | ﹤0.01% | 2729 |
|
|
2022
Q1 | $187K | Buy |
33,258
+7,377
| +29% | +$41.4K | ﹤0.01% | 2385 |
|
|
2021
Q4 | $157K | Buy |
25,881
+9,230
| +55% | +$56.1K | ﹤0.01% | 2203 |
|
|
2021
Q3 | $162K | Sell |
16,651
-8,431
| -34% | -$82.1K | ﹤0.01% | 2213 |
|
|
2021
Q2 | $358K | Buy |
25,082
+10,931
| +77% | +$156K | ﹤0.01% | 1779 |
|
|
2021
Q1 | $336K | Hold |
14,151
| – | – | ﹤0.01% | 1747 |
|
|
2020
Q4 | $189K | Hold |
14,151
| – | – | ﹤0.01% | 2016 |
|
|
2020
Q3 | $98.1K | Hold |
14,151
| – | – | ﹤0.01% | 2218 |
|
|
2020
Q2 | $174K | Buy |
+14,151
| New | +$174K | ﹤0.01% | 1986 |
|